L-GLUTAMIC ACID, 4-(3-FLUOROPROPYL)-, (4S)-
Stage IIIB Ovarian Cancer
Vanderbilt-Ingram Cancer CenterSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
245 Active assets in the Stage IIIB Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trabectedin AGO Research GmbH | Phase 4 | BBB |
Mirvetuximab Soravtansine AstraZeneca | Phase 3 | BBB |
Olaparib Imunon | Phase 4 | BB |
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Carboplatin University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
L-GLUTAMIC ACID, 4-(3-FLUOROPROPYL)-, (4S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →